STOCK TITAN

Tango Therapeutics Inc - TNGX STOCK NEWS

Welcome to our dedicated news page for Tango Therapeutics (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tango Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tango Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
Tango Therapeutics Inc

Nasdaq:TNGX

TNGX Rankings

TNGX Stock Data

785.44M
46.25M
13.51%
88.51%
9.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About TNGX

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util